Biomarkers of inflammation and coagulation predict non-AIDS-defining events in a prospective cohort of virologically suppressed people living with HIV.

IF 2.8 3区 医学 Q2 INFECTIOUS DISEASES
HIV Medicine Pub Date : 2025-03-25 DOI:10.1111/hiv.70017
Maria Saumoy, Analuz Fernandez, Juan Tiraboschi, Judith Peñafiel, José Luis Sánchez-Quesada, Jaime Vega, Benito García, Irene Soriano, Daniel Podzamczer, Arkaitz Imaz
{"title":"Biomarkers of inflammation and coagulation predict non-AIDS-defining events in a prospective cohort of virologically suppressed people living with HIV.","authors":"Maria Saumoy, Analuz Fernandez, Juan Tiraboschi, Judith Peñafiel, José Luis Sánchez-Quesada, Jaime Vega, Benito García, Irene Soriano, Daniel Podzamczer, Arkaitz Imaz","doi":"10.1111/hiv.70017","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the association between biomarkers of inflammation, coagulation and immune activation and the incidence of non-AIDS-defining events in a contemporary, antiretroviral therapy (ART)-experienced and virologically suppressed cohort of people living with HIV (PLWH).</p><p><strong>Methods: </strong>Prospective, observational cohort study. PLWH aged 30-70 years, with undetectable HIV viral load and no history of cardiovascular disease, randomly selected from outpatients were included. At baseline, plasma biomarkers (high-sensitivity C-reactive protein [hs-CRP], sCD163, sCD14, D-dimer, interleukin-6, soluble vascular cell adhesion molecule [s-VCAM] and lipoprotein-associated phospholipase A2 [Lp-PLA2] activity) were measured. Non-AIDS-defining events (non-AIDS cancer and cardiovascular events) and non-AIDS death were recorded until November 2022. Cumulative incidence was analysed for each endpoint and adjusted Cox regression used to assess associations.</p><p><strong>Results: </strong>A total of 438 participants were included: 81.1% men, mean age 50.4 (SD 10.1) years. The median time on treatment was 15.5 (interquartile range [IQR] 8.69; 19.7) years and with undetectable viral load 7.05 (IQR 4.03; 11.6) years. A total of 77 non-AIDS-defining events were recorded in 70 patients (38 non-AIDS cancers, 21 cardiovascular events, 37 non-AIDS deaths) in a median follow-up of 6.72 (IQR 6.02; 7.36) years. The cumulative incidence for non-AIDS cancer, cardiovascular event and non-AIDS death was 8.7% (95% CI 6.2-11.7), 4.79% (95% CI 2.99-7.24) and 8.47% (95% CI 6-11.5), respectively. In adjusted models, sCD163 was associated with incident non-AIDS cancer (hazard ratio [HR] 1.23, 95% CI 1.08-1.39), hs-CRP with incident cardiovascular events (HR 1.61, 95% CI 1.05-2.47), sCD163 (HR 1.28, 95% CI 1.11-1.46) and D-dimer (HR 1.75, 95% CI 1.08-2.86) with non-AIDS death.</p><p><strong>Conclusions: </strong>Biomarkers of inflammation, monocyte activation and coagulation were associated with non-AIDS-defining events in a contemporary and long-term suppressed cohort of PLWH.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/hiv.70017","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To assess the association between biomarkers of inflammation, coagulation and immune activation and the incidence of non-AIDS-defining events in a contemporary, antiretroviral therapy (ART)-experienced and virologically suppressed cohort of people living with HIV (PLWH).

Methods: Prospective, observational cohort study. PLWH aged 30-70 years, with undetectable HIV viral load and no history of cardiovascular disease, randomly selected from outpatients were included. At baseline, plasma biomarkers (high-sensitivity C-reactive protein [hs-CRP], sCD163, sCD14, D-dimer, interleukin-6, soluble vascular cell adhesion molecule [s-VCAM] and lipoprotein-associated phospholipase A2 [Lp-PLA2] activity) were measured. Non-AIDS-defining events (non-AIDS cancer and cardiovascular events) and non-AIDS death were recorded until November 2022. Cumulative incidence was analysed for each endpoint and adjusted Cox regression used to assess associations.

Results: A total of 438 participants were included: 81.1% men, mean age 50.4 (SD 10.1) years. The median time on treatment was 15.5 (interquartile range [IQR] 8.69; 19.7) years and with undetectable viral load 7.05 (IQR 4.03; 11.6) years. A total of 77 non-AIDS-defining events were recorded in 70 patients (38 non-AIDS cancers, 21 cardiovascular events, 37 non-AIDS deaths) in a median follow-up of 6.72 (IQR 6.02; 7.36) years. The cumulative incidence for non-AIDS cancer, cardiovascular event and non-AIDS death was 8.7% (95% CI 6.2-11.7), 4.79% (95% CI 2.99-7.24) and 8.47% (95% CI 6-11.5), respectively. In adjusted models, sCD163 was associated with incident non-AIDS cancer (hazard ratio [HR] 1.23, 95% CI 1.08-1.39), hs-CRP with incident cardiovascular events (HR 1.61, 95% CI 1.05-2.47), sCD163 (HR 1.28, 95% CI 1.11-1.46) and D-dimer (HR 1.75, 95% CI 1.08-2.86) with non-AIDS death.

Conclusions: Biomarkers of inflammation, monocyte activation and coagulation were associated with non-AIDS-defining events in a contemporary and long-term suppressed cohort of PLWH.

求助全文
约1分钟内获得全文 求助全文
来源期刊
HIV Medicine
HIV Medicine 医学-传染病学
CiteScore
5.10
自引率
10.00%
发文量
167
审稿时长
6-12 weeks
期刊介绍: HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信